Exact Sciences Corp(EXAS) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Current Price

$104.50

RSI

8.223

Beta:

1.318808

February 16, 2021
1.6B
94.8M

222.206 %
81.480 %
-310.818 %
-149.351 %

$2,900,440,000
$802,742,000
$417,320,000
$264,829,000
$99,012,000
$39,437,000
261.317 %
92.356 %
57.581 %
167.472 %
151.064 %

$-857,105,000
$-268,851,000
$-175,057,000
$-114,584,000
$-646,014,000
$-157,812,000
-68.633 %
-34.887 %
-34.545 %
463.791 %
-75.571 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.